Zobrazeno 1 - 10 of 121 pro vyhledávání: '"MESH: Clinical Trials as Topic"'
1
When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials
Autor: Célia Touraine, Benjamin Cuer, Thierry Conroy, Beata Juzyna, Sophie Gourgou, Caroline Mollevi
Publikováno v: BMC Medical Research Methodology
BMC Medical Research Methodology, 2023, 23 (1), pp.36. ⟨10.1186/s12874-023-01846-3⟩
Background Patient-reported outcomes such as health-related quality of life (HRQoL) are increasingly used as endpoints in randomized cancer clinical trials. However, the patients often drop out so that observation of the HRQoL longitudinal outcome en
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897f564449d3913c5bd520cdbf0c4bec
https://hal.science/hal-04104016
Zobrazit plný text záznamu
2
Weight gain stopping/switch rules for antiretroviral clinical trials
Autor: Luckyboy Mkhondwane, Polly Clayden, Alexandra Calmy, Samanta Lalla-Edwards, Marta Boffito, Nomathemba Chandiwana, Mark J. Siedner, Mary Carman, Simiso Sokhela, Celicia Serenata, Anton Pozniak, Saye Khoo, Bronwyn Bosch, Mohammed K. Ali, Vincent C. Marconi, Simon Collins, Eric Delaporte, Andrew Hill, Nkuli Mashabane, W D Francois Venter, Kenly Sekwese
Publikováno v: AIDS. Official journal of the international AIDS Society
AIDS. Official journal of the international AIDS Society, 2021, 35 (Supplement 2), pp.S183-S188. ⟨10.1097/QAD.0000000000003092⟩
AIDS
International audience; Obesity develops in a substantial number of people initiating and maintaining modern antiretroviral therapy. The comorbidities associated with obesity make significant weight gain and metabolic changes a major consideration in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db65f45975dbf5936457ebd5f412ad4a
https://doi.org/10.1097/qad.0000000000003221
Zobrazit plný text záznamu
4
An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination
Autor: Alfonso Tafur, Eduardo Ramacciotti, Jawed Fareed, Fabio Lievano, Grigoris T. Gerotziafas, Omer Iqbal, Charles A. Carter, Joseph Lewis, Meharvan Singh, Jeanine M. Walenga, Bruce E. Lewis, Walter Jeske, Bulent Kantarcioglu
Publikováno v: Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis, SAGE Publications, 2021, 27, pp.107602962110214. ⟨10.1177/10760296211021498⟩
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
International audience; Today the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global health problem. After more than a year with the pandemic, although our knowledge has pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b4f6439fdbd3c7439a10b51d6e78894
https://pubmed.ncbi.nlm.nih.gov/34060379
Zobrazit plný text záznamu
5
Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms
Autor: Sylvia Cohen-Kaminsky, P. Mendes-Ferreira, D. Santos-Ribeiro, Marceau Quatredeniers, Maria-Rosa Ghigna, Morad K. Nakhleh, Frédéric Perros
Publikováno v: Cells
Cells, MDPI, 2021, 10 (2), pp.477. ⟨10.3390/cells10020477⟩
Cells, Vol 10, Iss 477, p 477 (2021)
Cells, Vol. 10, no.2, p. 477 [1-22] (2021)
International audience; Pulmonary arterial hypertension (PAH) is a severe cardiovascular disease that is caused by the progressive occlusion of the distal pulmonary arteries, eventually leading to right heart failure and death. Almost 40% of patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0fd14d44cefe9c449b7010b105a0895
https://hal.archives-ouvertes.fr/hal-03419789
Zobrazit plný text záznamu
6
[Clinical trials that have changed our practices 2010-2020]
Autor: Nedla Allouache, E. Meyer, S. Servagi Vernat, M. Guigo, Julian Biau, A. Mège
Publikováno v: Cancer Radiothérapie
Cancer Radiothérapie, Elsevier Masson, 2020, 24 (6-7), pp.612-622. ⟨10.1016/j.canrad.2020.06.010⟩
Cancer/Radiothérapie
Cancer/Radiothérapie, Elsevier Masson, 2020, 24 (6-7), pp.612-622. ⟨10.1016/j.canrad.2020.06.010⟩
Resume Objectif de l’etude Cet article a pour objectif de decrire et de recenser les essais cliniques qui ont change nos pratiques dans les cancers du sein, les cancers urologiques, les cancers gynecologiques, les cancers des voies aerodigestives s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf4a119452840cce82dd0e87ef971e9
https://hal.archives-ouvertes.fr/hal-03052652
Zobrazit plný text záznamu
7
Efficacy of psychosocial interventions for children with ADHD and emotion dysregulation: a systematic review
Autor: Lucia Romo, Cécile Vacher, Allison Goujon, Diane Purper-Ouakil
Publikováno v: Psychiatry Research
Psychiatry Research, 2020, 291, pp.113151. ⟨10.1016/j.psychres.2020.113151⟩
Psychiatry Research, Elsevier, 2020, 291, pp.113151. ⟨10.1016/j.psychres.2020.113151⟩
International audience; Attention-Deficit Hyperactivity Disorder (ADHD) is frequently associated with emotion dysregulation (ED) that is characterized by excessive and inappropriate emotional reactions. Children with ADHD and ED present significant s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4b9f136d3b8904505cf3ff55cf9ffc
https://hal.umontpellier.fr/hal-03600753
Zobrazit plný text záznamu
8
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters
Autor: Laure Deyme, Florence Gattacceca, Dominique Barbolosi
Publikováno v: Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (1), pp.27-42. ⟨10.1007/s00280-018-3722-5⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (1), pp.27-42. ⟨10.1007/s00280-018-3722-5⟩
FOLFIRINOX regimen is commonly used in colorectal and more recently pancreatic cancer. However, FOLFIRINOX induces significant and dose-limiting toxic effects leading to empirical dose reduction and sometimes treatment discontinuation. Model-based FO
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15f49c7b034fc0de036e7e82cca4768
https://doi.org/10.1007/s00280-018-3722-5
Zobrazit plný text záznamu
9
Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol
Autor: Anne Spinewine, Jean-Baptiste Beuscart, Olivia Dalleur, Wilma Knol, Shane Cullinan, Stefanie Thevelin, Claudio Schneider, Benoît Boland, Nicolas Rodondi, Denis O'Mahony
Publikováno v: Clinical Interventions in Aging, Vol Volume 12, Pp 1379-1389 (2017)
Clinical Interventions in Aging
Clinical Interventions in Aging, 2017, Clinical interventions in aging, 12, pp.1379-1389. ⟨10.2147/CIA.S135481⟩
Clinical Interventions in Aging, Dove Medical Press, 2017, Clinical interventions in aging, 12, pp.1379-1389. ⟨10.2147/CIA.S135481⟩
Clinical Interventions in Aging, Vol. 12, p. 1379-1389 (2017)
Clinical Interventions in Aging, 12, 1379. Dove Medical Press Ltd.
Beuscart, Jean-Baptiste; Dalleur, Olivia; Boland, Benoit; Thevelin, Stefanie; Knol, Wilma; Cullinan, Shane; Schneider, Claudio; O'Mahony, Denis; Rodondi, Nicolas; Spinewine, Anne (2017). Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol. Clinical interventions in aging, 12, pp. 1379-1389. Dovepress 10.2147/CIA.S135481
Jean-Baptiste Beuscart,1 Olivia Dalleur,1 Benoit Boland,2 Stefanie Thevelin,1 Wilma Knol,3 Shane Cullinan,4 Claudio Schneider,5 Denis O’Mahony,6 Nicolas Rodondi,4,7 Anne Spinewine1,8 1Université catholique de Louvain, Louvain Drug Research Institu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3db94c78f49ef57f2743bf53ddf634d7
https://www.dovepress.com/development-of-a-core-outcome-set-for-medication-review-in-older-patie-peer-reviewed-article-CIA
Zobrazit plný text záznamu
10
The timeline of epigenetic drug discovery: from reality to dreams
Autor: Marianne G. Rots, A. Ganesan, María Berdasco, Paola B. Arimondo, Carmen Jerónimo
Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Clinical Epigenetics
Clinical Epigenetics, BioMed Central, 2019, 11 (1), pp.174. ⟨10.1186/s13148-019-0776-0⟩
Clinical Epigenetics, 2019, 11 (1), pp.174. ⟨10.1186/s13148-019-0776-0⟩
The flexibility of the epigenome has generated an enticing argument to explore its reversion through pharmacological treatments as a strategy to ameliorate disease phenotypes. All three families of epigenetic proteins—readers, writers, and erasers
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da45d7a237afb15483829aeb3ef082b
http://hdl.handle.net/2445/168017
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje